Chiesi Group is acquiring KalVista Pharmaceuticals for $27 per share in cash, representing a total value of approximately $1.9 billion 1 The acquisition includes Ekterly (sebetralstat), the first oral, on-demand plasma kallikrein inhibitor approved by the FDA for treating acute hereditary angioedema (HAE) attacks in patients 12 years and older 1 Ekterly received FDA approval in July 2025 and generated $49.1 million in sales in 2025 1 The deal terms represent a 36% premium on KalVista's 30-day average share price 1 The transaction is expected to close in the third quarter of 2026 2 This is Chiesi's most substantial acquisition to date in value terms 1 Hereditary angioedema is a rare genetic disorder causing days-long swelling attacks that can be extremely painful and life-threatening 1 Ekterly is the only on-demand treatment among competing HAE therapies; other options like Ionis' Dawnzera and CSL's Andembry are injectable prophylactic drugs administered re...
- Get link
- X
- Other Apps